Sm D1 Inhibitors
Sm D1 inhibitors are a class of chemical compounds that target a specific cellular process known as pre-mRNA splicing. Pre-mRNA splicing is a fundamental step in gene expression, where non-coding regions (introns) are removed from the pre-mRNA molecule, and the remaining coding regions (exons) are joined together to form mature mRNA. This process is essential for the production of functional proteins in eukaryotic cells. Sm D1 is one of the key components of the small nuclear ribonucleoprotein particles (snRNPs) involved in pre-mRNA splicing. These snRNPs play a crucial role in recognizing splice sites and facilitating the splicing process. Sm D1 inhibitors, therefore, specifically target and interfere with the function of Sm D1 in the spliceosome, disrupting the normal splicing process and leading to alterations in gene expression.
The mechanism of action of Sm D1 inhibitors typically involves binding to Sm D1 protein or interfering with its interactions within the spliceosome complex. By doing so, these inhibitors disrupt the assembly and function of the spliceosome, ultimately leading to splicing errors or exon skipping. This disruption can have profound effects on cellular processes, leading to the generation of aberrant mRNA molecules and the production of non-functional or abnormal proteins. Researchers study Sm D1 inhibitors to gain insights into the regulation of gene expression and the consequences of splicing dysregulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits SM d1 by binding to its ATP-binding site, thereby preventing the autophosphorylation of SM d1 kinase and subsequent downstream signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib targets the ATP-binding site of SM d1, inhibiting its kinase activity. It is a well-known tyrosine kinase inhibitor used for various cancers, particularly chronic myeloid leukemia. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits SM d1 and other kinases in the MAPK/ERK pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits multiple tyrosine kinases, including SM d1. It acts by binding to the ATP-binding site and is studied in the research of leukemia and other malignancies. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a selective SM d1 inhibitor that blocks its ATP-binding site, preventing its activation. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib inhibits SM d1 and other kinases in the angiogenic pathway. It reduces blood vessel formation in tumors and is employed in colorectal and other cancers. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a potent inhibitor of SM d1 and other kinases. It binds to the ATP pocket, inhibiting tyrosine kinase activity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib targets SM d1 and other kinases involved in angiogenesis. It inhibits tumor growth by preventing blood vessel formation and is used in renal cell carcinoma and soft tissue sarcomas. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Cabozantinib inhibits SM d1 and other kinases. It disrupts tumor cell proliferation, angiogenesis, and metastasis. It is employed in properties to reduce advanced renal cell carcinoma and medullary thyroid cancer. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits SM d1 and other kinases involved in tumor growth and angiogenesis. It is used for medullary thyroid cancer, targeting key pathways for cancer cell survival and growth. | ||||||